Watch for Q2 2026 revenue confirmation from Maryland and second state firefighter programs; current cash runway likely insufficient beyond 12 months without additional financings. The $5M private placement and up to $40M preferred purchase agreement provide near-term liquidity, but dilution risk persists.
Price Chart
Executive Summary
20/20 Biolabs reported Q1 2026 revenue of $0.4M, down 36% YoY and 55% below consensus, with EPS of -$0.28 vs. -$0.10 expected. Net loss widened to $2.2M from $0.8M, reflecting higher SG&A costs and non-cash charges. Management guided for a Q2 revenue rebound driven by state-funded firefighter screening programs, but provided no hard financial outlook.
Key Financial Metrics
Key Facts
- Revenue $353,375 in Q1 2026, down from $553,820 in Q1 2025
- Basic EPS -$0.28 vs consensus estimate -$0.10
- Net loss $2,174,836 vs $764,577 in prior year
- Gross margin compressed to 17.8% from 29.9%
- Cash and equivalents $4.2M at March 31, 2026, up from $1.0M at Dec 31, 2025
- Deferred revenue increased to ~$0.5M, providing revenue visibility
- Second state firefighter cancer screening program expected to contribute in future periods
Financial Impact
Revenue miss of 55% vs consensus; net loss more than doubled YoY
Risk Factors
- Revenue concentration on government firefighter screening programs
- Cash burn rate implies need for additional capital within 12 months
- Gross margin decline due to lower absorption of fixed costs
- Potential dilution from Series E preferred stock conversion and additional tranches
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-059526 |
| Document: ea0291642-8k_2020bio.htm | 0001213900-26-059526 |
| Document: 0001213900-26-059526-index-headers.html | 0001213900-26-059526 |
| Document: 0001213900-26-059526-index.html | 0001213900-26-059526 |
| Document: 0001213900-26-059526.txt | 0001213900-26-059526 |
| 8-K Data (Synthetic) | 0001213900-26-059526 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | DEFA14A | $0.2507 | awaiting T+5 | — | $0.2325 (−7.26%) |
Oct 21, 2026 5d ago | DEF 14A | $0.2507 | awaiting T+5 | — | $0.2325 (−7.26%) |
Aug 17, 2026 10w ago | 8-K | $0.5200 $0.5282 | ▲ +1.58% | ▲ +1.78% | $0.2325 (−55.29%) |
Aug 17, 2026 10w ago | Press Release | $0.5503 $0.5182 | ▼ −5.83% | ▼ −4.64% | $0.2325 (−57.75%) |
Aug 5, 2026 11w ago | 8-K | $0.4413 $0.4610 | ▲ +4.46% | ▲ +4.11% | $0.2325 (−47.31%) |
Jul 1, 2026 16w ago | 8-K | $0.6095 $0.5851 | ▼ −4.00% | ▼ −4.26% | $0.2325 (−61.85%) |
Jun 23, 2026 17w ago | DEFA14A | $0.5669 $0.6095 | ▼ −7.51% | ▼ −5.81% | $0.2325 (+58.99%) |
May 26, 2026 21w ago | 8-K | $0.9700 $0.8400 | ▼ −13.40% | ▼ −13.87% | $0.2325 (−76.03%) |
May 20, 2026 22w ago | 8-K | $1.21 $0.9500 | ▲ +21.49% | ▲ +23.09% | $0.2325 (+80.79%) |
May 20, 2026 22w ago | Press Release | $1.21 $0.9500 | ▲ +21.49% | ▲ +23.09% | $0.2325 (+80.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers